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Suppression of Epithelial-to-Mesenchymal Transitioning
Enhances Ex Vivo Reprogramming of Human Exocrine
Pancreatic Tissue Toward Functional Insulin-Producing
b-Like Cells
Maria João Lima,1 Kenneth R. Muir,1 Hilary M. Docherty,1 Robert Drummond,2 Neil W.A. McGowan,3
Shareen Forbes,4 Yves Heremans,5 Isabelle Houbracken,5 James A. Ross,2 Stuart J. Forbes,6
Philippe Ravassard,7,8 Harry Heimberg,5 John Casey,3 and Kevin Docherty1
Because of the lack of tissue available for islet transplantation,
new sources of b-cells have been sought for the treatment of type
1 diabetes. The aim of this study was to determine whether the
human exocrine-enriched fraction from the islet isolation proce-
dure could be reprogrammed to provide additional islet tissue for
transplantation. The exocrine-enriched cells rapidly dedifferenti-
ated in culture and grew as a mesenchymal monolayer. Genetic
lineage tracing conﬁrmed that these mesenchymal cells arose, in
part, through a process of epithelial-to-mesenchymal transition-
ing (EMT). A protocol was developed whereby transduction of
these mesenchymal cells with adenoviruses containing Pdx1,
Ngn3, MafA, and Pax4 generated a population of cells that were
enriched in glucagon-secreting a-like cells. Transdifferentiation or
reprogramming toward insulin-secreting b-cells was enhanced,
however, when using unpassaged cells in combination with inhi-
bition of EMT by inclusion of Rho-associated kinase (ROCK) and
transforming growth factor-b1 inhibitors. Resultant cells were able
to secrete insulin in response to glucose and on transplantation
were able to normalize blood glucose levels in streptozotocin di-
abetic NOD/SCID mice. In conclusion, reprogramming of human
exocrine-enriched tissue can be best achieved using fresh material
under conditions whereby EMT is inhibited, rather than allowing
the culture to expand as a mesenchymal monolayer. Diabetes
62:2821–2833, 2013
Since the establishment of the Edmonton protocol,islet transplantation has become an effective andviable therapeutic option for type 1 diabetes;however, it typically requires multiple donors to
achieve insulin independence (1). The lack of donor ma-
terial is a signiﬁcant problem and is fueling the drive to-
ward new sources of insulin-producing cells (2). Several
potential strategies exist for developing a replenishable
supply of b-cells. One of these strategies is through di-
rected differentiation of human embryonic stem cells or
induced pluripotent stem cells toward a b-cell lineage,
through an attempt to mimic the signaling pathways that
are triggered during pancreatic development (3–13). An-
other strategy involves transdifferentiating or reprogram-
ming one fully differentiated adult cell type to another
(14). Thus, insulin-producing cells can be generated from
liver (15–17), bone marrow (18), adipose tissue (19), and
cells derived from the umbilical cord (20). Of particular
relevance is the ﬁnding that murine pancreatic exocrine
cells can be reprogrammed (21) in vivo and in vitro toward
insulin-producing cells that are phenotypically similar to
b-cells. Most of the strategies applied to murine models
involved the exogenous expression of pancreatic tran-
scription factors (TFs) that are important for normal
endocrine pancreatic development (22,23). Although ex-
pression of the three transcription factors Pdx1, Ngn3, and
MafA in exocrine cells of murine pancreas resulted in
transdifferentiation of these cells toward the b-cell lineage
in vivo (24), the same TFs were unable to generate func-
tional b-cells in vitro (23), and further studies have shown
that additional TFs such as Nkx6.1, Pax4, or IA-1 (21–23)
and growth factors such as betacellulin, transforming
growth factor-b (TGF-b), and epidermal growth factor
(EGF) (25,26) may be important for generating functional
transdifferentiated b-cells in vitro.
The successful reprogramming of murine exocrine cells
has driven further studies aimed at the reprogramming of
human pancreatic tissue. Implementation of the Edmonton
protocol facilitated access to human cadaveric tissue that
results as a byproduct of the islet isolation procedure.
When placed in culture, this exocrine-enriched fraction
rapidly dedifferentiates to form a mesenchymal monolayer
that can be expanded through $20 passages (27). Several
studies have attempted to expand b-cell numbers through
redifferentiation of these human exocrine or islet-derived
mesenchymal cells (28–32). Despite some success in
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ORIGINAL ARTICLE
generating glucose-responsive insulin-producing cells from
both islet and exocrine cell sources, the ability of the
transdifferentiated cells to rescue diabetes in an animal
model is still unclear.
Here, we describe how cells of the adult human exo-
crine pancreas obtained from the islet isolation procedure
can be reprogrammed toward functional b-like cells in vitro.
When placed in culture, the acinar cells undergo epithelial-
to-mesenchymal transitioning (EMT), as demonstrated by
genetic lineage tracing, to form a monolayer of mesenchy-
mal cells. Efﬁcient reprogramming was achieved using
forced expression of four pancreatic TFs (Pdx1, Ngn3, Pax4,
and MafA) in combination with the growth factors beta-
cellulin and exendin-4, the vitamin nicotinamide, and small
molecules that facilitate DNA binding of TFs. We show that
this protocol generates predominantly glucagon-positive
cells, which respond to glucose in a manner similar to
that of pancreatic a-cells in vitro and in vivo. Importantly,
our studies demonstrate that reprogramming of pancreatic
exocrine cells toward functional insulin-producing cells
could be further enhanced by suppressing EMT using in-
hibitors of TGF-b1 and Rho-kinase signaling pathways. The
resultant cells secreted insulin in response to glucose and
successfully prevented the onset of diabetes when grafted in
a streptozotocin (STZ) diabetic mouse model.
RESEARCH DESIGN AND METHODS
Culture of human exocrine pancreatic fractions. All human tissue was
procured with appropriate ethical consent. Human pancreata (n = 16) were
isolated from brain-dead adult donors in the Scottish Islet Isolation Laboratory
(SNBTS, Edinburgh, U.K.). The mean donor age was 39.4 years (range, 23–61
years) and mean BMI was 27.2 kg/m2 (range, 22–36.5 kg/m2). After islet iso-
lation for clinical application, the low-purity exocrine fractions were trans-
ported to Aberdeen, where the cells were immediately plated at a density of
300,000 exocrine clusters on 75 cm2 tissue culture ﬂask (Greiner, Stonehouse,
U.K.) and cultured in serum-containing medium prepared using RPMI 1640
(Gibco, Life Technologies, Paisley, U.K.) supplemented with 10% FBS, 10
mmol/L HEPES, 1 mmol/L sodium pyruvate (all from Gibco), and 75 mmol/L
b-mercaptoethanol (Sigma Aldrich, Dorset, U.K.). Human exocrine pancreatic
cells were passaged every 7 days with a solution of Trypsin (0.05%) and EDTA
(0.02%; Gibco). Serum-free medium (SFM) was prepared using RPMI 1640
supplemented with 1% BSA (Sigma), 10 mg/mL insulin, and 5.5 mg/mL trans-
ferrin (both from Roche Diagnostics, West Sussex, U.K.).
Flow cytometry. Cells were incubated for 30 min with 10 mL of each primary
antibody (Supplementary Table 1), washed twice with PBS, and incubated for
a further 30 min with secondary antibodies (anti-mouse Ig; Silenus, Victoria,
Australia). They were then washed twice in PBS and resuspended in 1%
formaldehyde/PBS before analysis using a Beckman Coulter EPICS XL-MCL
Flow Cytometer.
Differentiation toward adipocytes, osteoblasts, and chondrocytes. For
differentiation, cells were trypsinized and resuspended in NH Adipodiff Me-
dium, NH Osteodiff Medium, or NH Chondrodiff Medium (all from Milentyi
Biotec, Surrey, U.K.), and processed as per the manufacturer’s instructions.
Genetic lineage tracing. The adenoviral vectors expressing Cre recombinase
under the control of the amylase promoter and the two lentiviral vectors
expressing Cre recombinase under the insulin promoter and a ﬂoxed STOP
dsRED promoter under control of the cytomegalovirus (CMV) promoter have
been described previously (33,34). The lentiviral ﬂoxed STOP dsRED was
generated by ligating dsRED into the BamHI/XhoI–digested pTrip-CMV-Lox-
STOP-Lox-EGFP-deltaU3 to replace EGFP.
Preparation of adenoviruses. Recombinant adenoviruses encoding the
mouse sequences of Pdx1, MafA, Ngn3, and Pax4 (35) were prepared using the
Ad-Easy system (Agilent Technologies, Edinburgh, U.K.). The adenoviruses
containing Pdx1 and Ngn3 also expressed GFP through a downstream CMV
promoter. Viral transduction was performed in SFM for 4 h at a multiplicity of
infection of 100 for each virus.
Quantitative RT-PCR. Quantitative (QRT-PCR was performed as pre-
viously described (22). Data were analyzed using the 22DDCT method. Sta-
tistical analysis was performed using PRISM software and the Student t test
or one-way ANOVA, followed by the Dunnet post hoc test, as appropriate.
TaqMan probes are listed in Supplementary Table 3.
Immunocytochemistry and immunohistochemistry. Immunocytochemistry
and immunohistochemistry were performed as previously described (13,22)
using the antibodies listed in Supplementary Table 2.
C-peptide and glucagon release studies. Glucagon or C-peptide levels were
measured using a human glucagon Quantikine ELISA kit (R&D Systems,
Abingdon, U.K.) or a human C-peptide ELISA kit (Millipore, Livingston, U.K.).
Insulin content. Cells were harvested in Trizol reagent (Invitrogen). DNA and
protein were extracted according to the manufacturer’s instructions. Insulin
was measured using an insulin ELISA kit (Millipore), and protein and DNA
were measured as previously described (22).
Animal studies. All animal experiments were performed under U.K. Home
Ofﬁce regulations and with the approval of the University of Aberdeen Ethics
Committee. Male 8- to 10-week-old NOD/SCID mice (NOD.CB17-Prkdcscid/
NCrHsd) were obtained from Harlan Laboratories (Blackthorn, U.K.) and
maintained on a 12-h light/dark cycle with ad libitum access to food. Mice were
rendered diabetic by one single intraperitoneal injection of STZ (150 mg/kg),
and transdifferentiated human cells were grafted under the left kidney capsule
as previously described (13).
RESULTS
Human exocrine-enriched tissue dedifferentiates in
culture to form a mesenchymal monolayer. The mate-
rial left over from the islet isolation procedure was mainly
composed of aggregates of exocrine cells, which were
epithelial in nature. There was some islet debris that could
be detected with dithizone or anti-insulin antibodies (Sup-
plementary Fig. 1A and B). The amount of insulin-positive
material varied between preparations but was never.2% of
the total tissue. When these exocrine-enriched pancreatic
fractions were placed in culture, the cells readily attached
to the dish and expanded into a monolayer of proliferative
cells with a morphology that resembled that of mesenchy-
mal stromal cells (MSCs), which could be further expanded
in vitro for at least 20 passages (Fig. 1A). This change in
morphology was associated with a loss of expression of
exocrine (amylase and cytokeratin 19 [CK19]), endocrine
(insulin), and epithelial (E-cadherin and epithelial cell ad-
hesion molecule) markers with a concomitant increase in
the mesenchymal markers Snai2 and a-smooth muscle actin
(Fig. 1B). Immunocytochemistry conﬁrmed the presence of
amylase-positive and CK19-positive exocrine cells as well as
vimentin-positive cells on day 2, the earliest time that could
be measured after plating (Fig. 2). The presence of vimentin
RNA (Fig. 1B) probably indicated the presence of endoge-
nous stromal cells in the exocrine fraction. The number of
amylase-positive and CK19-positive cells rapidly decreased,
whereas the vimentin-positive cells increased toward day 18.
Interestingly, on day 4 and on day 10, there was evidence for
cells that coexpressed amylase and vimentin or CK19 and
vimentin, suggesting that the exocrine cells were undergoing
dedifferentiation toward a mesenchymal phenotype. There
also were cells that coexpressed amylase and CK19, con-
ﬁrming a previous report of human acinar cell plasticity
(34). Flow cytometry analysis showed that .90% of the
passaged cells were positive for the main characteristic
mesenchymal stem cell surface markers, whereas endo-
thelial and hematopoietic cells were very rare in these
cultures (Supplementary Fig. 1B). In keeping with the
characteristics of MSCs (36), the pancreatic-derived mes-
enchymal cultures were able to differentiate toward cells
that stained positive for markers of adipose tissue (Oil Red
O), bone (alkaline phosphatase), and cartilage (aggregan)
(Supplementary Fig. 1D). To map the origins of the MSC
population, genetic lineage tracing was undertaken using an
adenovirus containing Cre-recombinase under the control
of the amylase promoter and a lentiviral vector containing
a CMV-driven dsRed reporter preceded by a ﬂoxed STOP
cassette blocking its expression (Fig. 3A). In acinar cells
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transduced by both viruses, dsRed is permanently expressed,
permitting continuous tracking of acinar cell fate even af-
ter amylase expression has stopped (34). The function of
this lineage tracing system was validated using AR42J-
B13 exocrine pancreatic cells (Supplementary Fig. 2A).
After transduction of the human exocrine-enriched cells
on day 1, dsRed-expressing cells were present on day 4
and time points thereafter (Fig. 3A). There was a massive
increase in the number of dsRed-positive cells between
day 4 and day 10, which was associated with a change
FIG. 1. Pancreatic exocrine fractions dedifferentiate toward mesenchymal cells in culture. A: Phase contrast images of exocrine fractions when
cultured in tissue culture dishes over a 14-day period. Scale bar = 50 mm. B: QRT-PCR analysis of pancreatic, epithelial, and mesenchymal markers
in cultured exocrine fractions from day 2 up to passage 7 after plating in tissue culture dishes. Data are presented as mean 6 SEM. Expression
levels are relative to glyceraldehyde 3-phosphate dehydrogenase (n = 3). AML, amylase; a-SMA, a-smooth muscle actin; D, day; ECAD, E-cadherin;
EPCAM, epithelial cell adhesion molecule; INS, insulin; P, passage; SNAI2, snail homolog 2; VIM, vimentin.
M.J. LIMA AND ASSOCIATES
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from a rounded morphology toward a more elongated
stellate shape. By day 10, the dsRed-positive cells consti-
tuted ;30% of the mesenchymal population. Immunocyto-
chemistry showed that already by day 3 the dsRed-positive
cells were positive for amylase, CK19, vimentin, and Ki67, a
marker for cell proliferation (Fig. 3C). By day 10, the dsRed
cells were all positive for vimentin and Ki67 and were neg-
ative for amylase and CK19. These results demonstrated
that the vimentin-positive mesenchymal monolayer was
derived by a process of EMT, although this does not rule
out the presence of stromal cells within the original
exocrine-enriched fractions.
The fate of b-cells also was mapped using a lentivirus
containing Cre-recombinase under control of the rat insulin
promoter in combination with the ﬂoxed STOP dsRed len-
tivirus described. The function of this system was evaluated
in Min-6 b-cells (Supplementary Fig. 2B). Using an islet-
enriched fraction, we were able to conﬁrm the previous
ﬁnding (37) that genetically labeled b-cells could trans-
differentiate via a process of EMT into vimentin-positive
mesenchymal cells (Supplementary Fig. 3). Therefore, it was
possible that any residual islet debris (or ductal cells) in the
exocrine-enriched fraction also could contribute to the MSC
population that expanded in culture.
Human exocrine MSCs can be reprogrammed toward
functional a-like cells. Having characterized in detail the
source of the pancreatic mesenchymal monolayer, we next
set out to reprogram these cells toward functional b-cells.
Ectopic expression of pancreatic TFs in cultured islet-
derived pancreatic MSCs previously has been accomplished
with infection with adenoviral vectors (38). In the current
study, a similar strategy was used to induce reprogram-
ming of the human exocrine-derived MSCs by introducing
TFs that control key stages in the developing pancreas,
namely, Pdx1, Ngn3, MafA, and Pax4 (referred to collec-
tively as the 4TFs). The individual adenoviruses transduced
the pancreatic MSCs with similar efﬁciency as evidenced by
immunocytochemistry (Supplementary Fig. 4). Individually,
the TFs had no effect on the expression of glucagon, insulin,
or somatostatin (Fig. 4A). However, in combination, the TFs
signiﬁcantly increased expression of glucagon with a maxi-
mal effect seen with the 4TFs (Fig. 4A). Under the same
conditions the TFs, either individually or in combination,
had no effect on the extremely low levels of expression of
insulin or somatostatin. Immunocytochemistry conﬁrmed
the expression of glucagon in 406 4.9% of the cells (n = 400
cells per donor, from 4 donor preparations) (Fig. 4B) and
the absence of insulin (data not shown). A control adenovirus
containing a GFP reporter had no effect on the expression
of insulin, C-peptide, or any other marker (Supplementary
Fig. 7B and C).
As previously described for islet-derived MSCs (28), the
exocrine-derived MSCs formed cluster-like structures in
SFM (Fig. 5A). This was accompanied by the upregula-
tion of several pancreatic markers, including the main
endocrine hormones glucagon, insulin, and somatostatin
FIG. 2. Dedifferentiation of pancreatic exocrine fractions is accompanied by EMT. Immunocytochemistry of plated pancreatic exocrine fractions
was performed from day 2 to day 18 in culture. The pancreatic exocrine markers amylase (AML) and CK19, the epithelial marker E-cadherin
(ECAD), and the mesenchymal marker vimentin (VIM) expressions were analyzed on days 2, 4, 10, and 18 of culture. Nuclei were counterstained
with DAPI. Scale bar = 20 mm.
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(Supplementary Fig. 5A), albeit at very low levels. This sug-
gested that the action of the exogenous TFs might be further
enhanced if the cells were cultured in the absence of serum.
In SFM, the 4TFs were able to induce glucagon and somato-
statin expression, but insulin levels were not signiﬁcantly al-
tered (Fig. 5B). However, in SFM, but not in serum-containing
medium, glucagon, insulin, and somatostatin expression was
increased by treatment with the 4TFs followed by addition
of betacellulin, exendin-4, and nicotinamide (collectively
referred to as BEN; Fig. 5B). These compounds previously
have been shown to induce formation of insulin-producing
cells from murine exocrine cells or adult islet cultures
(22,30). Individually, these compounds had little effect
(Supplementary Fig. 5B). Of importance was the observation
that the combination of the 4TFs and BEN in SFM increased
the endogenous expression levels of a number of endocrine
TFs, such as Pdx1, Pax4, Nkx6.1, and Pax6 (Fig. 5B), sug-
gesting that the cells had undergone transdifferentiation.
FIG. 3. Genetic lineage tracing of acinar amylase-positive cells in pancreatic exocrine fractions. A: Schematic representation of the two viral
vectors used for tracing amylase-positive cells. B: The dsRed-positive cells were monitored in culture for a 10-day period. The dsRed ﬂuorescence
(top row) and brightﬁeld images (bottom row) were analyzed at days 4, 6, 8, and 10. Scale bar = 50 mm. C: Immunocytochemistry was performed on
days 3, 7, and 10 on traced amylase-positive cells. The exocrine pancreatic markers amylase (AML) and CK19 were analyzed along with the
mesenchymal marker vimentin (VIM) and the proliferation marker ki67. Nuclei were counterstained with DAPI. Scale bar = 20 mm.
M.J. LIMA AND ASSOCIATES
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Chromatin-modifying agents enhance reprogramming.
To determine the effect of modulating the chromatin
structure within the MSC population before addition
of the adenoviruses, the cells were incubated for 72 h with
the DNA methyltransferase inhibitor 5-Aza-29deoxycytidine
and the histone deacetylase inhibitor sodium butyrate.
Under these conditions, the expression of all three hor-
mones was markedly enhanced when compared with the
addition of 4TFs and BEN alone (Fig. 5C). It was possible
to detect immunoreactive glucagon, but not insulin or
C-peptide, in the media of the resultant cells. Interestingly,
the secretion of glucagon was inhibited by high glucose,
suggesting that the reprogrammed cells contained some of
the properties of functional a-cells (Fig. 5D). However,
immunocytochemistry demonstrated that the majority of
the cells were multihormonal, expressing both glucagon
and C-peptide (Fig. 5E). No endocrine hormones were
found in nontreated exocrine-cultured cells (data not
shown). Blood glucose levels were constantly higher in
diabetic or nondiabetic NOD/SCID mice in which the
multihormonal cells had been grafted under the kidney
capsule. This is consistent with the elevated serum glu-
cagon levels detected in fasted diabetic and nondiabetic
animals (Supplementary Fig. 6).
FIG. 4. Ectopic expression of pancreatic TFs reprograms exocrine pancreatic MSCs into glucagon-positive cells. A: Passaged human exocrine
pancreatic fractions were plated in tissue culture dishes and subsequently transduced with different combinations of adenoviruses expressing the
pancreatic TFs Pdx1 (P), MafA (M), Pax4 (Px), and Ngn3 (N), each with a multiplicity of infection of 100. After 7 days, QRT-PCR was performed
and the data were expressed relative to glyceraldehyde 3-phosphate dehydrogenase and presented as mean 6 SEM (n = 3). *P < 0.05, **P < 0.01,
and ***P < 0.001. INS, insulin; GLC, glucagon; SST, somatostatin; N/A, nontreated samples. B: Exocrine cells treated with different combinations
of adenoviruses expressing P, M, and N in the presence or absence of Px were stained for the expression of glucagon, and cell nuclei were
counterstained with DAPI. Scale bar = 20 mm.
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FIG. 5. SFM and chromatin-modifying reagents enhance reprogramming of exocrine pancreatic MSCs toward glucagon-producing cells. A: Repre-
sentative phase contrast images of passaged exocrine pancreatic fractions cultured in serum-containing medium (SCM) or in SFM. Scale bar = 50 mm.
B: Passaged exocrine pancreatic cells were cultured in SCM or SFM and transduced with adenoviruses expressing the 4TFs. After 24 h, 1 nmol/L
betacellulin, 10 nmol/L exendin-4, and 10 mmol/L nicotinamide (BEN) were added to both SCM and SFM cultures. After 7 days, the cells were
harvested and QRT-PCR was performed. The data are expressed relative to glyceraldehyde 3-phosphate dehydrogenase and presented as mean 6
SEM (n = 3). *P< 0.05, **P< 0.01, and ***P< 0.001. C: Passaged exocrine pancreatic cells were cultured in SFM supplemented with 1 mmol/L 5-Aza-
29deoxycytidine (A) and/or 1 mmol/L sodium butyrate (Bu), transduced with adenoviruses (4TF), and treated with BEN as indicated. QRT-PCR was
performed and the data were expressed relative to glyceraldehyde 3-phosphate dehydrogenase and presented as mean 6 SEM (n = 3). ***P < 0.001
relative to nontreated samples (N/A). D: Glucagon secretion in culture medium of N/A or reprogrammed (A + Bu + 4TFs + BEN) exocrine cells in the
presence of basal (2.5 mmol/L) or after stimulation for 1 h with high (20 mmol/L) glucose. Glucagon levels were measured by ELISA and data
M.J. LIMA AND ASSOCIATES
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Collectively, these results indicate that the treatment
of pancreatic exocrine-derived MSCs with chromatin-
modifying agents, followed by TFs and BEN in SFM,
resulted in the formation of a-like cells that expressed
glucagon along with insulin. The cells exhibited some of the
functions of a-cells in an in vitro glucose release study and
increased blood glucose levels when grafted into NOD/
SCID mice. Reprogramming potential was speciﬁc to pan-
creatic exocrine-derived MSCs, because neither human
skin ﬁbroblasts nor human bone marrow MSCs responded
in a manner similar to that of the reprogramming protocol
(Supplementary Fig. 8). Thus, the cultured pancreatic
exocrine-derived MSCs must retain some memory of their
pancreatic origins.
Reversing or preventing EMT enhances reprogram-
ming toward functional b-like cells. These experiments
demonstrated that the pancreatic exocrine-derived MSCs
could be induced to transdifferentiate and that optimal
effects were achieved under serum-free conditions when
the cells formed epithelial-like clusters. This suggested that
reprogramming might be further optimized by promoting
a mesenchymal-to-epithelial transition or by inhibiting the
dedifferentiation of fresh exocrine-enriched epithelial
tissue.
The strategy for suppressing this process of dedif-
ferentiation involved culturing the cells in the presence of
small molecules that previously have been shown to inhibit
mesenchymal cell differentiation (39,40). Thus, inhibition of
activin receptor–like kinases by the selective inhibitor
SB431542 and the Rho-associated protein kinase inhibitor
Y27632 resulted in maintenance, for a 10-day period, of the
acinar and ductal cell markers amylase and CK19 at levels
similar to those observed in fresh tissue (Fig. 6). In keeping
with our supposition, treatment of freshly plated exocrine-
enriched tissue in SFM with SB431542, Y27632, 5-Aza-
29deoxycytidine, sodium butyrate, 4TF, and BEN resulted in
high levels of insulin, glucagon, and somatostatin, along
with Pdx1, Pax4, MafA, and Nkx6.1, when the cells were
analyzed after 10 days (Fig. 7A). These reprogrammed cells
were glucose-responsive, releasing C-peptide in a glucose-
dependent manner, and their insulin content was approxi-
mately four-fold higher than that of untreated cells (Fig. 7B
and C). Clusters of cells that were highly positive for insulin
and C-peptide were readily found in reprogrammed cul-
tures (Fig. 7D, a–f), and these cells were double-positive
for Pdx1 and insulin (Fig. 7D, g–i). Interestingly, some
glucagon-positive cells were found in the C-peptide–positive
cell clusters in a structure that closely resembles that of
a mature islet (Fig. 7D). Both types of the reprogrammed
endocrine cells generated by this protocol were mono-
hormonal and the majority of the cells in the clusters were
insulin-positive. This protocol generated an average of 18.3%
(64.9; n = 452 cells from 3 donor preparations) of insulin-
producing cells in the reprogrammed cultures. No signiﬁcant
levels of glucagon, insulin, or other pancreatic markers were
found in untreated or in exocrine cells transduced with
a control Ad-GFP vector on day 10 (Supplementary Fig. 7).
In summary, maintenance of the exocrine phenotype of
cultured exocrine cells at the start of the treatment greatly
improved the efﬁciency of reprogramming of exocrine
pancreatic cells toward monohormonal insulin-positive
cells, leading to the generation of glucose-responsive b-like
cells.
The in vivo function of the reprogrammed insulin-
producing cells was further determined by transplanting
these cells under the kidney capsule of NOD/SCID mice
that had been rendered diabetic with STZ 1 day before
surgery (Fig. 8A). Animals that were transplanted with
reprogrammed cells retained normal blood glucose levels
and maintained body weight throughout the course of the
experiment. Animals that were transplanted with non-
reprogrammed exocrine cells, or those that were not
transplanted with cells under the kidney capsule, exhibited
markedly elevated blood glucose levels associated with
weight loss (Fig. 8A). Removal of the transplanted kidney
after 30 days resulted in an increase in the blood glucose
levels of the animals transplanted with the reprogrammed
cells (Fig. 8A). Human C-peptide was present only in the
serum of fed mice that were transplanted with the reprog-
rammed insulin-producing cells (Fig. 8B) but was absent
from the blood when fasted, suggesting that the reprog-
rammed cells released insulin in a glucose-responsive
manner in vivo. Immunostaining of the grafted kidneys
showed that the transplanted cells formed a cluster-like
structure under the kidney capsule, where the center of the
structure was mainly composed of strongly positive insulin-
positive cells, with the majority of the glucagon-positive
cells localized in the periphery of the cluster (Fig. 8C). The
majority of the cells in this structure also were positive for
the pancreatic TF Pdx1 (Fig. 8D). Collectively, these data
support the conclusion that the exocrine pancreatic cells of
the adult human pancreas can be reprogrammed toward
functional insulin-producing cells. The reprogrammed cells
are able to ameliorate diabetes in a diabetic mouse model
and generate a cluster-like structure reminiscent of islets of
Langerhans.
Finally, to determine whether the reprogramming cock-
tail might be mediating an effect on the proliferation of
preexisting b-cells, reprogramming was performed on fresh
exocrine tissue in which residual b-cells were genetically
tagged with dsRed (Supplementary Fig. 9). Staining of the
traced cells revealed that insulin-producing cells were not
derived from preexisting b-cells, because none of the tag-
ged dsRed-positive cells were insulin-positive after the
reprogramming protocol. Even in the absence of reprog-
ramming, insulin expression was lost in preexisting b-cells
after 10 days in culture (Supplementary Fig. 9). In addition,
these lineage tracing experiments further support the role
of the soluble factors added in preventing EMT, because
dsRed-positive cell proliferation as a mesenchymal pop-
ulation was observed in untreated cultures but not in cul-
tures treated with the soluble factors alone (Supplementary
Fig. 9). To investigate if residual acinar amylase, which
could have a deleterious effect on transplantation, was
present in the reprogrammed cells, amylase expression
was investigated at the end of the reprogramming protocol
(Supplementary Fig. 9C). As observed for residual b-cells,
amylase expression disappeared in both reprogrammed
and untreated cells after the 10-day protocol (Supple-
mentary Fig. 9C), indicating that no traces of exocrine
markers were present in the reprogrammed cultures. No
evidence was found, by tracing of amylase-positive cells
represent the mean 6 SEM (n = 3). *P < 0.05. E: Glucagon and C-peptide immunoﬂuorescent staining in exocrine cells treated with 4TFs and BEN
in the presence of 5-Aza-29deoxycytidine and sodium butyrate. Scale bar = 20 mm. GLC, glucagon; INS, insulin; SST, somatostatin.
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during the reprogramming protocol, to support the view
that the newly generated b-like cells were derived from
preexisting acinar cells (Supplementary Fig. 10). These
data suggest that ductal cells are the most likely source of
the new insulin-producing cells; however, lineage-tracing
tools were not available to conﬁrm this hypothesis.
DISCUSSION
In this study, we cultured exocrine cells from the fractions
that are a by-product of the islet isolation procedure. Of
particular importance is the fact that all of these samples
were obtained from a single center and were prepared
under standardized operation procedures. When placed in
FIG. 6. The Rho-kinase and TGF-b1 pathway inhibitors suppress dedifferentiation of cultured pancreatic exocrine cells. A: Unpassaged exocrine
pancreatic cells were plated in tissue culture dishes. After 48 h to allow attachment, cells were untreated (N/A) or treated with 2 mmol/L r-kinase
inhibitor Y27632 (Y) and 10 mmol/L TGF-b1 inhibitor SB431542 (S) individually or in combination, and the cells were incubated for another 5 days.
Treated and N/A cells as well as baseline samples after 48 h in culture (day 0) were then harvested and RNA was extracted for QRT-PCR analysis
for expression of pancreatic, epithelial, and mesenchymal markers. Data are expressed relative to glyceraldehyde 3-phosphate dehydrogenase and
presented as mean 6 SEM (n = 3). A one-way ANOVA was performed with Dunnet post hoc test comparing treatment groups with N/A. A t test was
used to compare day 2 with Y 1 S. For all analyses, *P < 0.05, **P < 0.01. B: Immunocytochemistry for the pancreatic markers amylase (AML) and
Pdx1, the epithelial marker E-cadherin (ECAD), and the mesenchymal marker vimentin (VIM) in cultured exocrine pancreatic cells after 10 days in
the presence of Y27632 and SB431542 (Y+S). N/A cells also were analyzed for the same markers. Nuclei were counterstained with DAPI. Scale bar =
20 mm. EPCAM, epithelial cell adhesion molecule; GLC, glucagon; INS, insulin; SST, somatostatin.
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FIG. 7. The Rho-kinase and TGF-b1 pathway inhibitors enhance reprogramming toward insulin-producing cells. A: Unpassaged exocrine pancreatic cells
were plated in tissue culture dishes. The cells were then cultured for 72 h in SFM containing Y27632 (Y), SB431542 (S), 5-Aza-29deoxycytidine (A), and
sodium butyrate (Bu). They were then transduced with adenoviruses expressing the 4TFs and cultured for 7 days in SFM containing 1 nmol/L beta-
cellulin, 10 nmol/L exendin-4, and 10 mmol/L nicotinamide (BEN). Treated and untreated (N/A) cells then were harvested and RNA was extracted for
QRT-PCR analysis. Data are represented as mean 6 SEM and expressed relative to glyceraldehyde 3-phosphate dehydrogenase. *P < 0.05 or **P < 0.01
relative to N/A samples. B: Release of C-peptide to the medium in transdifferentiated (S+Y+A+Bu+4TFs+BEN) and N/A cells after incubation with 2.5 or
20 mmol/L of D-glucose for 1 h. The dashed line indicates the assay detection limit. Data are representative of triplicate experiments. ***P < 0.001.
C: Insulin content of transdifferentiated (S+Y+A+Bu+4TFs+BEN) and N/A cells normalized to the DNA content of each sample. Data are representative
of triplicate experiments. *P < 0.05. D: Immunostaining for insulin (INS) (panels a–c and g–i), C-peptide (C–PEP) (panels d–f), Pdx1 (panels g–i), and
glucagon (GLC) (panels d–f) of transdifferentiated cells in culture. Nuclei were counterstained with DAPI. Data are representative of triplicate
experiments. Inlets show a 23 higher magniﬁcation image of stained clusters. Scale bar = 50 mm. AML, amylase; E-CAD, E-cadherin; SST, somatostatin.
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FIG. 8. Reprogrammed insulin-producing cells prevent STZ-induced diabetes in vivo.A: Body weight and blood glucose levels weremeasured in NOD/SCID
mice grafted with transdifferentiated cells or exocrine pancreatic cells or in nongrafted mice (Ctrl) over a 38-day period after surgery. A single dose (150
mg/kg) of STZ was administered 1 day before surgery. Transdifferentiated cells, n = 5; exocrine pancreatic cells, n = 3; control, n = 2. B: Serum C-peptide
levels were measured in NOD/SCID mice grafted with transdifferentiated cells or exocrine pancreatic cells and in nongrafted mice (Ctrl) after a 4-h
starvation period (fast) or with ad libitum feeding (fed) conditions. Transdifferentiated cells, n = 5; exocrine pancreatic cells, n = 3; control, n = 2.
C: Immunostaining for insulin and glucagon of grafted kidneys after kidney removal. Yellow dashed lines indicate the border between the kidney (k) and
the graft. The red circle in panel a indicates the difference in glucagon staining observed within the cluster. A 53 higher magniﬁcation of the cells inside
this circle is shown in panel c; 103 higher magniﬁcations of the cells inside (panel e) and outside (panel f) the circle are shown. Panel d shows a 53
higher magniﬁcation of insulin staining within the area marked by the red square in panel b. A 103 higher magniﬁcation of insulin-positive cells present
in the center of the cluster is shown in panel g. Scale bar for panels a and b = 100 mm. Scale bar for panels c–g = 20 mm. D: Immunoﬂuorescent staining
for Pdx1 in kidneys grafted with transdifferentiated cells. Scale bar = 50 mm. A 53 higher magniﬁcation inlet is shown. Ctrl, control; Exoc Cells, exocrine
pancreatic cells; GLC, glucagon; INS, insulin; Transdif Cells, transdifferentiated cells.
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culture, the exocrine pancreatic cells rapidly began to
coexpress the mesenchymal marker vimentin with a quick
decline in epithelial markers as the culture became uni-
formly single-positive for vimentin. Similar results were
observed when a human islet-enriched fraction was used as
starting material. Our immunocytochemistry and genetic
lineage tracing results showing that cells transiently express
both epithelial and mesenchymal markers clearly support
the view that the human pancreatic MSC population arises
from a combination of endogenous stromal cells and through
EMT of all pancreatic epithelial cell types. This differs from
the case of rodents, in which genetic lineage tracing studies
have found no evidence for pancreatic MSCs arising via
EMT from b-cells (41,42).
It previously has been shown that pancreatic MSCs de-
rived from human isolated islets can be induced to redif-
ferentiate when plated on extracellular matrix in response
to a cocktail of growth factors under serum-free conditions
(28,30,43,44), although it has been argued that this occurs
only to a limited extent (45). We hypothesized that the
capacity of pancreatic exocrine-derived MSCs to trans-
differentiate could be enhanced by using ectopic expression
of pancreatic TFs that are known to deﬁne and maintain the
identity of islet cell types (46). Our approach was inﬂuenced
by in vivo studies of the transdifferentiation of liver (15–17)
and pancreatic exocrine cells (24) in the mouse. Our ﬁrst
major ﬁnding was that pretreatment of the cells with
chromatin-modifying reagents, followed by adenoviruses
expressing Pdx1, Ngn3, Pax4, and MafA, along with two
growth factors, betacellulin and exendin 4, and the water-
soluble vitamin nicotinamide could convert the pancreatic
MSCs into glucagon-positive a-like cells. These multihormonal
cells secreted glucagon in a physiological manner, whereby
hormone release was inhibited by high-glucose concentrations
in the medium. When grafted into NOD/SCID mice, these
a-like cells continued to secrete glucagon in response to
changes in serum glucose levels, even when the animals were
rendered diabetic with streptozotocin. It was surprising that
the resultant cell population was mainly composed of a-like
cells because the inclusion in our reprogramming cocktail of
Pax4, which favors the production of b-cells (47), was
designed to tip the balance toward the b-cell lineage. During
embryogenesis, a-cells and b-cells arise from a common
progenitor that expresses Ngn3. There is a narrow compe-
tence window for Ngn3 expression, the length of which can
markedly affect the generation of different endocrine cell
types (48). In the case of the reprogrammed exocrine cells,
perhaps the temporal expression of Ngn3 may dominate,
and this could be addressed in further experiments by
modulating expression of the exogenous Ngn3.
Our second major ﬁnding, however, was that the pro-
duction of functional b-cells could be achieved by pre-
venting dedifferentiation of the exocrine cells toward MSCs.
Treatment of the exocrine-cultured cells with factors that
inhibit TGF-b1 and Rho-kinase pathways (39,40), which are
known to be key players in mesenchymal differentiation,
prevented a decrease in exocrine marker expression in the
cultures of exocrine-derived cells and the substantial ex-
pansion of pancreatic MSCs. When applied to these cells
that more closely resemble the exocrine pancreas, the
reprogramming protocol that previously had resulted in the
formation of functional glucagon-producing cells gave rise
to functional insulin-producing cells that were able to se-
crete insulin in response to glucose and normalize glucose
levels in a streptozotocin diabetic NOD/SCID mouse model.
Importantly, the levels of human C-peptide that were
secreted in vitro in the presence of 20 mmol/L glucose
were 0.4 ng/mL, which compares well with the amount of
insulin released by equivalent numbers of cultured human
islets (49).
In conclusion, we have developed a protocol that led to
the successful reprogramming of human exocrine pancre-
atic cells toward functional b-like cells capable of prevent-
ing the onset of diabetes in a mouse diabetic model. The
important ﬁnding was that fresh tissue that was pre-
dominantly epithelial could be efﬁciently reprogrammed
toward functional b-cells, whereas expansion as a mes-
enchymal monolayer was less efﬁcient, generating pre-
dominantly a-like cells. The clinical importance of these
ﬁndings is that it may be possible to reprogram the exocrine
pancreatic tissue that is normally discarded after the islet
isolation procedure and, in a matter of weeks, provide
a second batch of islets for the recipient derived from the
same donor. This would obviate the need for a second do-
nor preparation, thus increasing overall supply and also
preventing additional potential donor-speciﬁc immune
problems. Overall, cryopreserved exocrine tissue holds
promise as a donor-recipient–speciﬁc top-up supply of
islets for further use as the graft function deteriorates.
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